NCT01502631已完成2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 65
- 主要终点
- Total Spinal Cord Independence Measure, Version III (SCIM III) Score Following Treatment With SUN13837 Injection or Placebo in Adult With Acute Spinal Cord Injury
研究概览
简要总结
The purpose of this research study is to gather scientific information about the effectiveness of the study drug, SUN13837 Injection, when compared with the placebo (inactive substance) in participants with acute spinal cord injury.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 16 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute traumatic injury to the cervical neurological spinal cord as follows:
- •American Spinal Injury Association Impairment Scale A (AIS A) with a level of injury at either cervical level C4, C5, C6, C7 (for C4, the participant must have at least 1 point of motor activity within the zone of partial preservation (ZPP) inclusive of C5 to thoracic level 1 [T1]). In addition, the AIS A participant may be included if ALL of the following are present 1) the most caudal intact sensory segment (both pinprick and light touch) is C3, 2) at least one side (right or left) has both intact pinprick and light touch sensation in the C4 dermatome, AND 3) at least 1 point of motor activity within the ZPP inclusive of C5 to T1
- •American Spinal Injury Association Impairment Scale B or C (AIS B or C) with a neurological level of injury at either C3, C4, C5, C6, C7, or C8 AND a total LEMS of 5 or fewer motor points
- •Closed single traumatic spinal cord injury occurring within 12 hours of first dosing
- •Male or female cervical AIS A participants ≥ 16 to ≤ 80 years and male or female cervical AIS B or C participants ≥16 to ≤70 years
- •Females of childbearing potential and males must agree to maintain adequate contraception for the first 35 days of the study
排除标准
- •Unable to obtain informed consent (either from the participant or from the participant's legally authorized representative [LAR])
- •Women who are breastfeeding (if unwilling to stop for the first 35 days of the study) or who are pregnant
- •Coma or significant impairment in the level of consciousness that interferes with the performance or interpretation of protocol specified assessments
- •Any disease, concomitant injury, or condition that interferes with the performance or interpretation of the protocol specified assessments
- •Unable, as determined by the investigator, or unwilling to discontinue use of potent P-glycoprotein (P-gp) inhibitors for the first 35 days of the study
- •Unable, as determined by the investigator, or unwilling to discontinue use of potent cytochrome P450 (CYP) 3A4/5 inducers for the first 35 days of the study
- •Renal compromise (serum creatinine greater than 1.5 times the age- and sex-appropriate upper limit of normal [ULN]) at screening before the first dose of study drug
- •Severe Hepatic dysfunction (serum alanine transaminase [ALT], aspartate transaminase [AST], and/or gamma-glutamyltransferase [GGT] ALL greater than 2.5 times the age- and sex-appropriate ULN) or hepatic impairment (detectable ascites, serum bilirubin greater than 2 mg/dL, serum albumin less than 3.5 g/dL, and prothrombin time prolonged by more than 6 seconds above the ULN for the local laboratory in the absence of anticoagulant therapy) at screening before the first dose of study drug
- •Concomitant spinal cord injury or abnormality as determined by routine imaging:
- •Conclusive radiological evidence of complete spinal cord transection
- •Multiple injuries to the neurological spinal cord at different levels
- •History of symptomatic cervical spinal stenosis with myelopathy as a factor confounding participant assessment
- •Unlikely to be available for follow-up as specified in the protocol
- •Participated in a previous clinical study and received an investigational product within 30 days of screening
- •Previous exposure to SUN13837
- •Allergy to SUN13837 or any of its excipients
- •Any other issue which, in the opinion of the investigator, made the participant unsuitable for study participation.
研究组 & 干预措施
SUN13837
Active Comparator
干预措施: SUN13837 injection (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Total Spinal Cord Independence Measure, Version III (SCIM III) Score Following Treatment With SUN13837 Injection or Placebo in Adult With Acute Spinal Cord Injury
时间窗: Week 2, week 4, week 8 and week 16 post dose.
The SCIM III is a comprehensive rating scale that measures the ability of participants with spinal cord injury to perform everyday tasks. The SCIM III has 19 items that assess 3 domains: Self-Care (6 items, scores range from 0 to 20), Respiration and Sphincter Management (4 items, scores range from 0 to 40), and Mobility (9 items, scores range from 0 to 40). The total SCIM score ranges from 0 to a maximum of 100 points in an individual with a fully functional spinal cord. A score of 0 indicates a worse outcome and a score of 100 indicates a better outcome. An improvement of at least 4 points of the total SCIM showed a small significant improvement, and 10 points showed a substantial improvement.
次要结局
- Sensitivity Analyses of Total Spinal Cord Independence Measure, Version III (SCIM III) Score at Week 16 by Treatment Group(Week 16 post dose)
- Change From Baseline of Total Motor Score (TMS) of International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Following Treatment With SUN13837 Injection or Placebo in Adult With Acute Spinal Cord Injury(Baseline to Day 3, Week 2, Week 4, Week 8, and Week 16 post dose.)
- Self-Care and Mobility Subscale Scores of Spinal Cord Independence Measure, Version III (SCIM III) Score Following Treatment With SUN13837 Injection or Placebo in Adult With Acute Spinal Cord Injury(Week 2, Week 4, Week 8, and Week 16 post dose.)
- Upper Extremity Motor Scores (UEMS) of International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Following Treatment With SUN13837 Injection or Placebo in Adult With Acute Spinal Cord(Baseline to Day 3, Week 2, Week 4, Week 8, and Week 16 post dose.)
- Lower Extremity Motor Scores (LEMS) of International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Following Treatment With SUN13837 Injection or Placebo in Adult With Acute Spinal Cord Injury(Baseline to Day 3, Week 2, Week 4, Week 8, and Week 16 post dose.)
- Incidence of Adverse Events Reported in ≥ 20% of Participants Following Treatment With SUN13837 Injection or Placebo in Adult With Acute Spinal Cord Injury(Baseline up to approximately Day 182 post dose.)
研究者
相似试验
已完成
2 期
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic DermatitisAtopic DermatitisNCT01756898Daiichi Sankyo370
已完成
3 期
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)GoutNCT00856206Regeneron Pharmaceuticals1,315
已完成
3 期
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)GoutNCT00958438Regeneron Pharmaceuticals248
已完成
3 期
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1Intercritical GoutNCT00829829Regeneron Pharmaceuticals241
已完成
3 期
Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)Diabetes Mellitus, Type 2NCT00106704Merck Sharp & Dohme LLC441